{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:01Z","timestamp":1792417381834,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023YFS0257"],"award-info":[{"award-number":["2023YFS0257"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clgc.2026.102688","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:36:39Z","timestamp":1790404599000},"page":"102688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Surgical Enablement in Renal Cell Carcinoma: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Yucong","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7358-4377","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clgc.2026.102688_bib0001","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology Guidelines on renal cell Carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized Renal cancer: evaluation, management, and follow-up: AUA guideline: part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102688_bib0003","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of tumors of the urinary system and male genital organs-part A: renal, penile, and testicular tumors","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102688_bib0004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2010.12.013","article-title":"A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma","volume":"59","author":"Van Poppel","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102688_bib0005","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2016.08.060","article-title":"Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies","volume":"71","author":"Mir","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eururo.2015.11.034","article-title":"Systematic review of surgical management of nonmetastatic renal cell carcinoma with Vena Caval thrombus","volume":"70","author":"Lardas","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clgc.2026.102688_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2026.102688_bib0009","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102688_bib0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2026.102688_bib0011","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102688_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clgc.2026.102688_bib0013","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2026.102688_bib0014","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.clgc.2026.102688_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.clgc.2026.102688_bib0016","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clgc.2026.102688_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","article-title":"Neoadjuvant Nivolumab in patients with high-risk nonmetastatic renal cell carcinoma","volume":"5","author":"Gorin","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102688_bib0017","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1464-410X.2010.09357.x","article-title":"Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery","volume":"106","author":"Silberstein","year":"2010","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.juro.2015.03.096","article-title":"A phase II study of Pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma","volume":"194","author":"Rini","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102688_bib0019","doi-asserted-by":"crossref","first-page":"112.e15","DOI":"10.1016\/j.urolonc.2014.11.009","article-title":"Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma","volume":"33","author":"Lane","year":"2015","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102688_bib0020","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bju.14581","article-title":"Evaluation of axitinib to downstage cT2a renal tumors and allow partial nephrectomy: a phase II study","volume":"123","author":"Lebacle","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102688_bib0021","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bju.16217","article-title":"PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy","volume":"133","author":"Hakimi","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102688_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2023.05.016","article-title":"Selective use of neoadjuvant targeted therapy is associated with greater achievement of partial nephrectomy for high-complexity renal masses in a solitary kidney","volume":"54","author":"Attawettayanon","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.clgc.2026.102688_bib0023","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.juro.2010.05.041","article-title":"Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma","volume":"184","author":"Hellenthal","year":"2010","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102688_bib0024","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s43018-025-00922-5","article-title":"Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial","volume":"6","author":"Bilen","year":"2025","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102688_bib0025","first-page":"1729","article-title":"Presurgical treatment with sunitinib for renal cell carcinoma with a level III\/IV vena cava tumor thrombus","volume":"32","author":"Horn","year":"2012","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.clgc.2026.102688_bib0026","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CAD.0000000000000627","article-title":"Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study","volume":"29","author":"Terakawa","year":"2018","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.clgc.2026.102688_bib0027","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.21873\/invivo.11698","article-title":"Presurgical pazopanib improves surgical outcomes for renal cell carcinoma with high-level IVC tumor thrombosis","volume":"33","author":"Okamura","year":"2019","journal-title":"In Vivo"},{"issue":"6","key":"10.1016\/j.clgc.2026.102688_bib0028","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","article-title":"A phase II study of neoadjuvant axitinib for reducing the extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)","volume":"127","author":"Stewart","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2026.102688_bib0029","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2147\/OTT.S158114","article-title":"Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus","volume":"11","author":"Peng","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"5","key":"10.1016\/j.clgc.2026.102688_bib0030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0031","article-title":"Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clgc.2026.102688_bib0032","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00423-016-1543-8","article-title":"Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma","volume":"402","author":"Hatiboglu","year":"2017","journal-title":"Langenbecks Arch Surg"},{"issue":"22","key":"10.1016\/j.clgc.2026.102688_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132852","article-title":"Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma","volume":"5","author":"Wood","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.clgc.2026.102688_bib0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II study of neoadjuvant Nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102688_bib0036","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102688_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102353","article-title":"Clinical outcomes and safety profile of neoadjuvant PD-1 inhibitors combined with VEGFR-TKI versus VEGFR-TKI in nonmetastatic renal cell carcinoma","volume":"23","author":"Ng","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102688_bib0038","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/s41598-025-86712-6","article-title":"Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.clgc.2026.102688_bib0039","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1308\/rcsann.2021.0251","article-title":"A comparison of cytoreductive and non-cytoreductive management strategies for nephron-sparing approaches to tumors in solitary kidneys","volume":"104","author":"Nayak","year":"2022","journal-title":"Ann R Coll Surg Engl"},{"issue":"5","key":"10.1016\/j.clgc.2026.102688_bib0040","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.21037\/tau-21-406","article-title":"Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0041","doi-asserted-by":"crossref","first-page":"123.e11","DOI":"10.1016\/j.urolonc.2025.11.001","article-title":"Neoadjuvant pembrolizumab and tyrosine kinase inhibitor to facilitate imperative partial nephrectomy for renal cell carcinoma","volume":"44","author":"Gonzalez","year":"2026","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102688_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.70095","article-title":"Neoadjuvant tislelizumab plus pazopanib in renal cell carcinoma with venous tumor thrombus: a retrospective study","volume":"6","author":"Dilixiati","year":"2025","journal-title":"BJUI Compass"},{"issue":"6","key":"10.1016\/j.clgc.2026.102688_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008475","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2026.102688_bib0044","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.21037\/tau-23-203","article-title":"Presurgical immune-oncology\/tyrosine kinase inhibitor combination therapy for renal cell carcinoma with a vena cava tumor thrombus: a single-institution case series","volume":"12","author":"Urabe","year":"2023","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102688_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12885-026-15581-7","article-title":"Response assessment of patients with locally advanced renal cell carcinoma receiving prior systemic therapy","volume":"26","author":"Seifert","year":"2026","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102688_bib0046","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41392-024-01990-2","article-title":"Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.clgc.2026.102688_bib0047","article-title":"Neoadjuvant Toripalimab plus Axitinib for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: a combined analysis of two phase II","volume":"7","author":"Peng","year":"2026","journal-title":"Clinical Trials. MedComm"},{"issue":"3","key":"10.1016\/j.clgc.2026.102688_bib0048","article-title":"Tislelizumab combined with Axitinib in neoadjuvant treatment of locally advanced clear","volume":"7","author":"Yang","year":"2026","journal-title":"Cell Renal Cell Carcinoma: A Single-Center, Phase II Clinical Study. MedComm"},{"issue":"2","key":"10.1016\/j.clgc.2026.102688_bib0049","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.21873\/invivo.12798","article-title":"Immune checkpoint inhibitor combination therapy for renal cell carcinomas with concomitant inferior Vena cava thrombi","volume":"36","author":"Yoshida","year":"2022","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.clgc.2026.102688_bib0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2026.102688_bib0051","unstructured":"ClinicalTrials.gov. Neoadjuvant pembrolizumab and axitinib in renal cell carcinoma with inferior vena cava tumor thrombus (NEOPAX). NCT05969496. Updated 13 April 2026. Accessed 22 September 2026."},{"key":"10.1016\/j.clgc.2026.102688_bib0052","unstructured":"ClinicalTrials.gov. Neoadjuvant Zanzalintinib plus Nivolumab in patients with locally advanced and\/or inoperable clear cell renal cell carcinoma (EXPLORE-RCC). NCT06794229. Updated 4 June 2026. Accessed 22 September 2026."},{"key":"10.1016\/j.clgc.2026.102688_bib0053","unstructured":"National Cancer Institute. Testing the safety and feasibility of Botensilimab and Balstilimab before surgery for clear cell renal cell carcinoma (NEO RoBOT Trial). NCT07516366. Accessed 22 September 2026."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:00:52Z","timestamp":1792414852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1558767326001886"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102688","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Surgical Enablement in Renal Cell Carcinoma: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102688"}}